.Anavex Life Sciences’ lead asset has failed to significantly improve disease characteristics in a pediatric Rett syndrome trial, with the company pointing the blame toward a high placebo effect.The New York City-based biotech's stock cratered 30% since the data was shared earlier today, tumbling from $9.32 per share at market close Friday to $6.55 as of 10:30 a.m. ET.
.Anavex Life Sciences’ lead asset has failed to significantly...
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.40 |
Change
-0.255(1.87%) |
Mkt cap ! $1.719B | |||
| Open | High | Low | Value | Volume |
| $13.68 | $13.68 | $13.35 | $890.9K | 66.13K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17 | $13.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.40 | 113 | 4 |
View Market Depth
| Last trade - 11.33am 18/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |